Lantheus Medical Imaging Patent-Cliff Exposure & CMS Drug Spending Portfolio

Lantheus Medical Imaging (US): 2 reconciled FDA prescription therapies, $7.1M 2024 CMS Part D & Medicaid spend, and 33 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2037-01-01
2024 CMS Total Public Spend$7.1M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$7.1M
California HCAI SB 17 Filings33 WAC filings (max 23.6% 2-yr change)